Progesterone only pills: an effective contraceptive option for lactating women


  • Michelle Fonseca Department of Obstetrics and Gynecology, LTMMC and GH, Sion, Mumbai, Maharashtra, India
  • Prasad Yeshwant Deshmukh Department of Obstetrics and Gynecology, LTMMC and GH, Sion, Mumbai, Maharashtra, India
  • Deepali Kharat Department of Obstetrics and Gynecology, LTMMC and GH, Sion, Mumbai, Maharashtra, India



Amenorrhoea, Breastfeeding, Irregular spotting, Progesterone only pills


Background: Progesteone only pills (POP) are the most suitable for breastfeeding women as they have no effect on quality and quantity of breast milk in lactating women or on infant growth as well.

Methods: A study was conducted on post partum lactating women over a period of 6 months at a tertiary care hospital in Mumbai. Post partum women were called for follow up in the post natal OPD and were counseled about temporary and permanent spacing methods.

Results: Progesterone only pills are an acceptable and convenient means of temporary contraception / spacing during lactation period in motivated patients who do not want IUCDs or Injectables or are undecided about permanent methods of family planning.

Conclusions: Low Dose progesterone only minipill is both effective and acceptable to breast feeding women. It may be used as a temporary spacing method in women who do not prefer an IUD but who are motivated to be complaint with its use.


Horta B, Bahl R, Martines J, Victora C. Evidence of the long-term effects of breastfeeding; systematic review and meta-analysis. World Health Organization; Geneva, Switzerland;2007.

Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler RJ et al. Breastfeeding and the use of human milk. Pediatrics. 2005;115(2):496-506.

Diaz S, Peralta O, Juez G, Herreros C, Casado ME, Salvatierra AM et al. Fertility regulation in nursing women: III. Short-term influence of a low-dose combined oral contraceptive upon lactation and infant growth. Contraception. 1983;27(1):1-11.

Morbidity and Mortality Weekly Report (MMWR). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period. Weekly. 2011;60(26);878-883

Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev. 2011;(5):CD004861.

New Mexico Department of Health. New Mexico Pregnancy Risk Assessment Monitoring System (PRAMS). Surveillance Report 2008. Retrieved May 9, 2011. Available at

Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D. Contraceptive technology. 20th ed. Ardent Media Inc; New York;2012.

ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice bulletin #73, Use of Hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-72.

WHO. WHO medical eligibility criteria. Fifth edition 2015. Available at

International Planned Parenthood Federation: directory of hormonal contraceptives medical and service delivery guidelines. 3rd ed. 2004. Available at






Original Research Articles